WeTrials
Recruiting

A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms

What is this study?

This study is testing a new combination of a targeted medicine called venetoclax and standard chemotherapy drugs to treat fast-growing blood cancers like acute myeloid leukemia. Researchers want to find the best and safest doses of these medications working together to destroy cancer cells more effectively.

Who can participate?

You may be able to join if you have been diagnosed with acute myeloid leukemia or a related high-risk blood cancer that is newly diagnosed, has returned, or has not responded to previous treatments. Certain health conditions, such as untreated infections or cancer that has spread to the brain, mean you cannot participate.

What will happen?

Participants will receive a combination of venetoclax and several chemotherapy medications, along with supportive drugs to help the body make white blood cells. You will also have regular medical tests, including blood draws and bone marrow checks, to see how well the treatment is working.

Where and when?

This study is currently recruiting patients and takes place in Seattle, Washington, United States. Your care team will give you all the specific details about the schedule and clinic visits.

Key Points
  • 1Tests a combination of venetoclax and chemotherapy for blood cancers
  • 2Aims to find the safest and most effective doses for patients
  • 3Currently recruiting participants in Seattle, Washington

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute LeukemiaMyeloid NeoplasmRelapsed Acute Biphenotypic LeukemiaRelapsed Acute Myeloid LeukemiaRelapsed Mixed Phenotype Acute LeukemiaRelapsed Myeloid NeoplasmRefractory Acute Biphenotypic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Mixed Phenotype Acute LeukemiaRefractory Myeloid NeoplasmRecurrent Myeloid Sarcoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.